SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging as a nostalgic yet serious cultural movement, leveraging its 2011 origin as the internet's original Bitcoin parody to capture investor attention. The community is actively highlighting its deep historical roots, recent high-profile whale endorsements, and its transition onto modern blockchain infrastructure as key factors driving its momentum.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community leans into its established two-year Solana history, using persistent meme-driven engagement and organic social promotion to rally holders. Investors are actively discussing the token's presence on the Jupiter strict list and its role within the broader meme coin meta, with discussions centered on whale accumulation and long-term community dedication.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is seeing increased community chatter surrounding its role as a key liquidity hub on the Base ecosystem, with investors closely watching potential catalyst events and revenue growth. Community sentiment remains mixed, as some participants express frustration with current price action while others double down on accumulation strategies in anticipation of long-term utility gains.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining traction as a high-volatility meme coin on the Solana network, with the community actively celebrating its early growth, developer accessibility, and airdrop events. Traders are focused on pushing the token past key market cap milestones while encouraging engagement through aggressive social media activity and strategic buying during dips.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

ORCA is experiencing a massive short squeeze following a significant uptick in trading volume and public attention related to its role in the Solana ecosystem. Community members are actively debating the token's explosive price action, with some focused on the potential for continued momentum while others caution against the volatility of this pump.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors react to the FDA lifting the clinical hold on its Phase 3 MAGNITUDE trial, signaling a key de-risking event for the company's heart disease gene therapy pipeline. The community is actively discussing the stock's significant short interest and the potential for a recovery toward previous highs as traders weigh clinical progress against broader macroeconomic volatility.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

The TRUMP meme coin is facing severe downward pressure and community backlash, with investors reacting to allegations of a "pump and dump" scheme and frustration over the coin's utility following recent high-profile events. The conversation is dominated by intense political polarization, with critics citing the coin as part of a broader pattern of financial exploitation while supporters continue to debate its role as a speculative asset.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is experiencing heightened investor attention driven by sustained trading volume, fueling persistent community speculation regarding a potential buyout or strategic partnership. While investors are closely monitoring clinical developments and the company's financial runway, the market remains reactive to these recurring M&A rumors despite a lack of formal announcements.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as holders actively accumulate during a consolidation phase, citing the project's unique "phygital" strategy and retail presence as key pillars for long-term growth. While some investors debate the risks of meme coin volatility, the community is heavily focused on potential breakout triggers and the project's ongoing brand expansion efforts.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco is currently trending as investors focus on the company's central role in the nuclear energy sector, bolstered by significant federal investments in reactor buildouts and sustained long-term demand for uranium as a baseload power source for AI infrastructure. The community is actively discussing Cameco's strong institutional support and its strategic positioning within the nuclear fuel cycle while weighing the stock's recent price appreciation against long-term growth prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Q4 net loss widened to $61.9 million from $59.2 million, primarily driven by higher R&amp;D expense.</li><li>R&amp;D expense for the quarter increased by $28.7 million to $63.9 million.</li><li>The company remains focused on completing enrollment in its BCG-naïve randomized trial and targeting a BLA filing by Q4 2026, CEO said.</li></ul>Shares of ImmunityBio, Inc. (IBRX) drew investor focus in pre-market trading on Monday after the pharmaceutical firm reported better-than-expected fourth-quarter results.The stock gained 11% with <a href="https://stocktwits.com/symbol/IBRX">IBRX</a> among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">ANKTIVA Boosts Q4 Revenue</h2>Net product revenue for Q4 surged 431% to $38.3 million, above Wall Street’s estimates of $37.8 million, according to Fiscal.ai data. ImmunityBio cited the increase in revenue to the sales of ANKTIVA, a U.S. Food and Drug Administration (FDA) approved immunotherapy for bladder and lung cancer.However, Q4 net loss widened to $61.9 million from $59.2 million, primarily driven by higher R&amp;D expense, the company said. R&amp;D expense for the quarter increased by $28.7 million to $63.9 million."As we advance toward initial international commercial activities, we remain focused on disciplined execution: completing enrollment in our BCG-naïve randomized trial with a BLA filing targeted by Q4&nbsp;2026, expanding the ANKTIVA label into lung cancer and lymphopenia, and converting our 700%&nbsp;revenue growth trajectory into durable, long-term value for shareholders," said Richard Adcock, President and CEO of ImmunityBio.<h2 class="st-heading-2">Anktiva Expansion Plans</h2>Earlier on Monday, Chairman Soon-Shiong <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-open-week-on-high-chairman-teases-anktiva-3-year-expansion-plans-cancer-breakthrough/cZRtSeQR4Us/amp">said</a> on X that a detailed press release about a three-year expansion plan for the BioShield platform, including Anktiva, is expected to be released.&nbsp;He described it as a strong start to the year and discussed Anktiva’s IL-15 science, noting its importance in natural killer cell therapies. He added that IL-15 has long been viewed as a promising cancer-fighting cytokine and said Anktiva now uses it effectively.ImmunityBio has partnered with Biopharma and Cigalah Healthcare to launch Anktiva in Saudi Arabia and expand across the MENA region. The drug recently won approvals in Saudi Arabia and the European Union, bringing total approvals to 33 countries.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for IBRX on Stocktwits remained in the 'extremely bullish' zone, amid 'extremely high' message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/IBRX_jpg_a6c9147f3c.webp" alt="IBRX.jpg" width="934" height="109"><figcaption>IBRX's Sentiment Meter and Message Volumes on Feb. 24, 2026 | Source: Stocktwits</figcaption></figure>One user compared the stock to AAPL, stating that they were "adding aggressively."<stembedurl>https://stocktwits.com/BixbyKnolls/message/645637611</stembedurl>Another user expected a bigger rally.<stembedurl>https://stocktwits.com/Guitars7/message/645634938</stembedurl>Year-to-date, the stock has surged around 380%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tirx-stock-tian-ruixiang-rally-business-combination/cZRtvrnR4yl">This Nano-Cap Stock Shot Up 130% Today – What Triggered The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 11%

Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data

VBB
Valkyrie ETF Trust II - Valkyrie Balance Sheet Opportunities ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest VBB News

VBBValkyrie ETF Trust II - Valkyrie Balance Sheet Opportunities ETF